Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS.

abstract：:HSV can cause oral lesions that exacerbate chemotherapy-related mucositis. Intravenous acyclovir is effective in preventing HSV reactivations, but expensive. Valacyclovir has good bioavailability and has not been studied for prophylaxis of HSV among PCT patients. We compared the efficacy and costs of valacyclovir in p...

journal_title：Bone marrow transplantation

authors： Dignani MC,Mykietiuk A,Michelet M,Intile D,Mammana L,Desmery P,Milone G,Pavlovsky S

更新日期：2002-02-01 00:00:00

abstract：:Preparative regimens without total body irradiation (TBI) have been reported for alternative donor hemopoietic stem cell transplants (HSCT). Between 7 September 1994 and 7 June 1999 48 patients with advanced hematologic malignancies were conditioned with thiotepa (THIO) 15 mg/kg, cyclophosphamide (CY) 150 mg/kg and an...

journal_title：Bone marrow transplantation

authors： Lamparelli T,van Lint MT,Gualandi F,Raiola AM,Barbanti M,Sacchi N,Ficai G,Ghinatti C,Bregante S,Berisso G,Dominietto A,Di Grazia C,Bruno B,Sessarego M,Casarino L,Verdiani S,Bacigalupo A

更新日期：2000-12-01 00:00:00

abstract：:Treatment with allogeneic hematopoietic stem cell transplantation (HSCT) is associated with short and long-term toxicities that can result in alterations in sexual functioning. The aims of this prospective evaluation were to determine: (1) associations between HSCT and increased sexual dysfunction 1 year after treatme...

journal_title：Bone marrow transplantation

authors： Noerskov KH,Schjødt I,Syrjala KL,Jarden M

更新日期：2016-06-01 00:00:00

abstract：:The role of high-dose therapy and autologous stem cell transplantation (ASCT) in the treatment of patients with Ewing's sarcoma (EWS) remains uncertain. From November 1985 to September 1994, 13 patients aged 16-30 years (median 20.5) received high-dose melphalan (HDM) 140-200 mg/m2 +/- 500 cGy TBI followed by ASCT for...

journal_title：Bone marrow transplantation

authors： Stewart DA,Gyonyor E,Paterson AH,Arthur K,Temple W,Schachar NS,Klassen J,Brown C,Russell JA

更新日期：1996-08-01 00:00:00

abstract：:Relapse rates in patients after autologous bone marrow transplantation (BMT) for acute myeloid leukemia (AML) continue to be high despite the use of aggressive conditioning regimens. Based on studies in the murine system a clinical protocol was developed that utilizes immunotherapy to obtain a graft-versus-leukemia (G...

journal_title：Bone marrow transplantation

authors： Klingemann HG,Eaves CJ,Barnett MJ,Eaves AC,Hogge DE,Nantel SH,Reece E,Shepherd JD,Sutherland HJ,Phillips GL

更新日期：1994-09-01 00:00:00

abstract：:Suboptimal neutrophil and platelet recovery after unrelated donor umbilical cord blood transplantation (UCBT) may be due in part to an impaired microenvironment after intensive chemoradiotherapy. In an attempt to speed hematopoietic recovery, 15 pediatric patients with high-risk acute leukemia were enrolled on a singl...

journal_title：Bone marrow transplantation

authors： Macmillan ML,Blazar BR,DeFor TE,Wagner JE

更新日期：2009-03-01 00:00:00

abstract：:A potential problem of autologous transplantation in the treatment of multiple myeloma (MM) is the infusion of tumor cells. CD34+ selection has been used to purge autografts in MM and it is also possible to reduce tumour cell contamination of autografts by cytotoxic drug therapy prior to peripheral blood stem cell (PB...

journal_title：Bone marrow transplantation

authors： Dyson PG,Horvath N,Joshua D,Barrow L,Van Holst NG,Brown R,Gibson J,To LB

更新日期：2000-06-01 00:00:00

abstract：:The impact of graft-versus-host reactivity on the outcome of bone marrow transplantation (BMT) was analysed in rabbits of defined major histocompatibility (RLA) types by injecting 10(8) parental type cells into newborn F1 recipients. Distinctive allotypic determinants on immunoglobulin (Ig) molecules of donor and reci...

journal_title：Bone marrow transplantation

authors： Adler LT,Annaratone LJ 3rd,LeBeau MM

更新日期：1990-01-01 00:00:00

abstract：:For several haematological malignancies, allogeneic stem cell transplantation is the treatment of choice. In most cases an HLA-identical sibling is required. If the mother of a patient is pregnant, cord blood from a related donor, which can be used for stem cell transplantation, might be obtainable in the near future....

journal_title：Bone marrow transplantation

authors： van den Berg H,Verjaal M,Boer K,Lardy NM

更新日期：2000-03-01 00:00:00

abstract：:Knowledge of the vital role of adenosine deaminase in lymphatic tissues has led to the development of enzyme inhibitors for treatment of lymphoid neoplasms. Deoxycoformycin is a potent ADA inhibitor and has been shown to be active in acute lymphoblastic leukemia at high doses but associated with unpredictable toxicity...

journal_title：Bone marrow transplantation

authors： Ho AD,Thaler J,Willemze R,Lauria F,Derossi G,Kuse R,Stryckmans P,Blanc CM,Cataldo F,McVie G

更新日期：1989-01-01 00:00:00

abstract：:Infectious complications due to adenovirus are of increasing concern after allogeneic stem cell transplantation. Over the past 4 years, we have modified our conditioning regimens to use alemtuzumab in preference to anti-thymocyte globulin (ATG) for pediatric patients receiving stem cell transplants from alternate dono...

journal_title：Bone marrow transplantation

authors： Myers GD,Krance RA,Weiss H,Kuehnle I,Demmler G,Heslop HE,Bollard CM

更新日期：2005-12-01 00:00:00

abstract：:Post transplantation constrictive bronchiolitis (PTCB) is the most common pulmonary complication among long-term survivors of allogeneic hematopoietic stem cell transplantation (HSCT). It is a late manifestation of GVHD. Its treatment with high-dose systemic corticosteroids and other immunosuppressive regimens is asso...

journal_title：Bone marrow transplantation

authors： Bashoura L,Gupta S,Jain A,Couriel DR,Komanduri KV,Eapen GA,Safdar A,Broglio KR,Adachi R,Dickey BF

更新日期：2008-01-01 00:00:00

abstract：:Many factors, including lower risk of GVHD, rapid availability of 4/6-6/6 matched cord blood (CB) units and incremental gains in the outcomes, have led to an increasing use of CB transplantation (CBT) to treat many patients who lack fully matched adult BM donors. A large electronically searchable worldwide inventory o...

journal_title：Bone marrow transplantation

authors： Prasad VK,Kurtzberg J

更新日期：2009-11-01 00:00:00

abstract：:Cytomegalovirus (CMV) antigenemia and quantitative real-time polymerase chain reaction (PCR) were compared for monitoring of CMV reactivation after allogeneic stem cell transplantation. The number of CMV antigen-positive cells by the antigenemia assay and the level of CMV DNA by real-time PCR correlated well. The sens...

journal_title：Bone marrow transplantation

authors： Yakushiji K,Gondo H,Kamezaki K,Shigematsu K,Hayashi S,Kuroiwa M,Taniguchi S,Ohno Y,Takase K,Numata A,Aoki K,Kato K,Nagafuji K,Shimoda K,Okamura T,Kinukawa N,Kasuga N,Sata M,Harada M

更新日期：2002-04-01 00:00:00

abstract：:The transplant policy for unrelated donor (UD) BMT at Leiden Paediatrics' SCT-Centre consisted of the use of (1) fully HLA-matched donors or, if not available, HLA-class I matched and/or cytotoxic T-lymphocyte precursor (CTLp)-negative donors and (2) protective isolation of the recipient and antimicrobial suppression ...

journal_title：Bone marrow transplantation

authors： Vossen JM,Donker AE,Heemskerk MB,Lie JL,van Weel-Sipman MH,Bredius RG,Bakker JD,Egeler RM,Oudshoorn M

更新日期：2010-01-01 00:00:00

abstract：:HLA-identical sibling donor transplantation remains the treatment of choice for Wiskott-Aldrich Syndrome (WAS). Since 1990, utilization of alternative donor sources has increased significantly. We report the hematopoietic cell transplantation (HCT) outcomes of 47 patients with WAS treated at a single center since 1990...

journal_title：Bone marrow transplantation

authors： Shin CR,Kim MO,Li D,Bleesing JJ,Harris R,Mehta P,Jodele S,Jordan MB,Marsh RA,Davies SM,Filipovich AH

更新日期：2012-11-01 00:00:00

abstract：:A double-blind double-dummy, comparative study was carried out in 30 patients receiving highly emetogenic fast dose rate, single fraction total body irradiation prior to bone marrow transplantation. Patients were randomised into one of two groups, receiving either granisetron, a specific 5-HT3 antagonist or a combinat...

journal_title：Bone marrow transplantation

authors： Prentice HG,Cunningham S,Gandhi L,Cunningham J,Collis C,Hamon MD

更新日期：1995-03-01 00:00:00

abstract：:Pegase 03 is a multicenter prospective randomized phase III trial evaluating the impact of first-line high-dose chemotherapy (HDC) with stem cell support on overall survival (OS), disease-free survival (DFS) and response rate in 308 patients with histologically proven metastatic breast cancer responding to induction t...

journal_title：Bone marrow transplantation

authors： Biron P,Durand M,Roché H,Delozier T,Battista C,Fargeot P,Spaeth D,Bachelot T,Poiget E,Monnot F,Tanguy ML,Curé H

更新日期：2008-03-01 00:00:00

abstract：:A total of 81 adults with acute myeloid leukemia (AML) (47% favorable karyotypes) were autografted in first remission after melphalan-total body irradiation, having received 0 (n=7), 1 (n=19), 2 (n=51), or 3 (n=4) consolidation chemotherapy cycles before harvest. The cumulative 5-year incidences of relapse and transpl...

journal_title：Bone marrow transplantation

authors： Mehta J,Powles R,Sirohi B,Treleaven J,Swansbury GJ,Kulkarni S,Saso R,Singhal S

更新日期：2003-07-01 00:00:00

abstract：:We previously reported an synergism between methotrexate and tacrolimus (FK506) in preventing graft-versus-host disease (GVHD) in dogs given DLA-nonidentical unrelated marrow grafts after 9.2 Gy of total body irradiation (TBI). Methotrexate was given at 0.4 mg/kg i.v. on days 1, 3, 6 and 11 and FK506 at 0.15 mg/kg/day...

journal_title：Bone marrow transplantation

authors： Yu C,Storb R,Deeg HJ,Graham TC,Scheuning FG,Huss R,Seidel K,Fitzsimmons WE

更新日期：1996-04-01 00:00:00

abstract：:To identify a correlation between metaphase cytogenetics and relapse after reduced intensity conditioning (RIC) allotransplant for patients with multiple myeloma, data on 60 patients (median age 52) who received grafts from a sibling (n = 49) or unrelated donor (n = 11) were analyzed. Fifty-three patients (88%) showed...

journal_title：Bone marrow transplantation

authors： Lee CK,Zangari M,Fassas A,Thertulien R,Talamo G,Badros A,Cottler-Fox M,van Rhee F,Barlogie B,Tricot G

更新日期：2006-03-01 00:00:00

abstract：:Patients who develop veno-occlusive disease (VOD) of the liver may have low plasma levels of the natural anticoagulants protein C and antithrombin III, but large vessel thromboses are not commonly reported in these patients. We reviewed the records of 1847 consecutive patients for evidence of portal vein thrombosis. E...

journal_title：Bone marrow transplantation

authors： Kikuchi K,Rudolph R,Murakami C,Kowdley K,McDonald GB

更新日期：2002-02-01 00:00:00

abstract：:A patient with malignant lymphoma, large cell type and extensive bone marrow necrosis at presentation is reported. Bone marrow necrosis persisted even after a complete remission was induced with standard chemotherapy. Because of this adverse prognostic factor, circulating stem cells were collected and reinfused follow...

journal_title：Bone marrow transplantation

authors： Khan AM,Yamase H,Tutschka PJ,Bilgrami S

更新日期：1997-05-01 00:00:00

abstract：:We have used a standardized 21-day expansion protocol to produce cytokine-induced killer (CIK) cells starting from very small amounts of nucleated cells (approximately 15 x 10(6) cells) isolated from cord blood. Mononuclear cells are stimulated with anti CD3 (OKT3) and IFNgamma and then expanded with IL-2. Moreover, w...

journal_title：Bone marrow transplantation

authors： Introna M,Franceschetti M,Ciocca A,Borleri G,Conti E,Golay J,Rambaldi A

更新日期：2006-11-01 00:00:00

abstract：:Still, many physicians give 4 cycles of combination therapy to multiple myeloma patients prior to collection of stem cells for autologous bone marrow transplant. This tradition originates from older doxorubicin-containing regiments which limited the number of cycles due to cumulative cardiotoxicity. Using older regime...

journal_title：Bone marrow transplantation

authors： Tageja N,Korde N,Kazandjian D,Panch S,Manasanch E,Bhutani M,Kwok M,Mailankody S,Yuan C,Stetler-Stevenson M,Leitman SF,Sportes C,Landgren O

更新日期：2018-11-01 00:00:00

abstract：:We conducted a prospective randomized clinical trial to assess the mobilizing efficacy of filgrastim, lenograstim and molgramostim following a disease-specific chemotherapy regimen. Mobilization consisted of high-dose cyclophosphamide in 45 cases (44%), and cisplatin/ifosfamide/etoposide or vinblastine in 22 (21%), fo...

journal_title：Bone marrow transplantation

authors： Kopf B,De Giorgi U,Vertogen B,Monti G,Molinari A,Turci D,Dazzi C,Leoni M,Tienghi A,Cariello A,Argnani M,Frassineti L,Scarpi E,Rosti G,Marangolo M

更新日期：2006-09-01 00:00:00

abstract：:Considerable evidence in preclinical models as well as in human transplantation now suggests that donor-derived natural killer (NK) cells can contribute to alloimmune recognition of recipient residual tumour cells. This makes the NK cell population an attractive target for in vitro or in vivo manipulations, in order t...

journal_title：Bone marrow transplantation

authors： Lassailly F,Sielleur I,Blaise D,Chabannon C

更新日期：2005-01-01 00:00:00

abstract：:Donor lymphocyte infusions (DLI) are used to treat relapsed haematological diseases after allogeneic stem cell transplantation (SCT). We treated seven patients with DLI for indolent non-Hodgkin's lymphoma relapsed after SCT. In available blood and bone marrow samples, lymphoma cells were analysed by real-time quantita...

journal_title：Bone marrow transplantation

authors： Mandigers CM,Verdonck LF,Meijerink JP,Dekker AW,Schattenberg AV,Raemaekers JM

更新日期：2003-12-01 00:00:00

abstract：:Nine normal bone marrow donors aged 7-166 months (median 69 months) received autologous red cells which had been removed from their marrow harvest after collection. The median volume of marrow removed from the donors was 18.6 ml/kg which was equivalent to a median blood volume loss of 23.3%. Three infant donors were t...

journal_title：Bone marrow transplantation

authors： Chan KW,Herd SL,Stanley CE,Wadsworth LD

更新日期：1992-05-01 00:00:00

abstract：:A 51-year-old patient with refractory CLL elected to participate in a trial of nonmyeloablative trans- plantation from an HLA-matched unrelated donor. He received low-dose fludarabine/TBI, with infusion of donor PBPC and cyclosporin (CsA)/MMF. Early post transplant he experienced explosive tumor growth with respirator...

journal_title：Bone marrow transplantation

authors： Nieto Y,Bearman SI,Shpall EJ,Jones RB,Cagnoni PJ,Rabinovitch RA,McSweeney PA

更新日期：2001-12-01 00:00:00